Emery P, et al. - SB4 (Benepali, Brenzys) is a biosimilar of reference etanercept (ETN). This extension study assessed the long-term efficacy, safety and immunogenicity when continuing SB4 vs switching from ETN to SB4 for the treatment of rheumatoid arthritis (RA). Over 2 years of duration, SB4 was found to be effective and was well tolerated in RA patients. Between the SB4/SB4 and ETN/SB4 groups, efficacy, safety and immunogenicity were comparable, demonstrating no risk associated with switching patients from ETN to SB4.